Watch LBRX. Know when insiders buy.
One email the day a filing lands. Free.
LBRX
LB PHARMACEUTICALS INC
39.23
−1.77 −4.32%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.3BP/E 280.2DIV YIELD —FCF YIELD -6.55%REV TTM —NET INCOME −$85.7MNET CASH —52W 14.61 – 49.48SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | — | −$51.6M | — | -1.71 | −$37.6M | $363K | −$38M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | — | −$19.1M | — | -0.67 | −$23.3M | $32K | −$23.3M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$11.5M | — | 3.13 | −$18.1M | $40K | −$18.1M | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | — | −$3.6M | — | -0.61 | −$3.4M | $0 | −$3.4M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | — | −$4.9M | — | -13.58 | −$5.6M | −$9K | −$5.6M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | — | −$5.3M | — | -14.79 | −$8.1M | $21K | −$8.1M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | — | −$5.1M | — | -14.00 | −$5.7M | $238K | −$5.9M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | — | −$14.2M | — | -39.49 | — | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | — | −$27.6M | — | — | — | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | — | −$16.2M | — | — | — | — | — | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$25.2M | — | -3.13 | −$35.2M | $52K | −$35.3M | — | — |
| FY2024 · to Dec 31 | — | — | — | −$63.1M | — | -176.15 | −$53.1M | $769K | −$53.8M | — | — |
Every number comes from LB PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.